

IX BIOPHARMA LTD.
(Company Registration No. 200405621W)
(Incorporated in the Republic of Singapore)

**PROPOSED RENOUNCEABLE NON-UNDERWRITTEN RIGHTS CUM WARRANTS ISSUE
– DESPATCH OF NOTIFICATION AND APPLICATION FORMS**

Unless otherwise defined, all capitalised terms herein shall have the same meanings as in the Company's announcements dated 6 June 2024, 11 June 2024, 18 June 2024 and 26 June 2024 in relation to the Rights cum Warrants Issue (the "Earlier Announcements") and the Offer Information Statement dated 26 June 2024. Any reference to the time of day herein shall be a reference to Singapore time.

The board of directors (the "**Board**") of iX Biopharma Ltd. (the "**Company**") refers to the Earlier Announcements in relation to the Rights cum Warrants Issue undertaken by the Company.

The Board wishes to announce that a printed copy of the Notification, together with the ARE or the PAL, as the case may be, have been despatched to Entitled Shareholders today. To access the Offer Information Statement, Entitled Shareholders may refer to the instructions set out in the Notification.

Entitled Depositors who do not receive the ARE or ARS together with the Notification, may contact The Central Depository (Pte) Limited via its hotline at +65 6535 7511 or via email at asksgx@sgx.com, on Mondays to Fridays from 8.30 a.m. to 5.00 p.m., during the period from the date the Rights cum Warrants Issue commences up to 5.30 p.m. on 15 July 2024 (or such other time(s) and/or date(s) as may be announced from time to time by or on behalf of the Company).

Entitled Scripholders who do not receive the PAL together with the Notification, may obtain a copy from the Share Registrar, Tricor Barbinder Share Registration Services at 9 Raffles Place, Republic Plaza, Tower 1, #26-01, Singapore 048619, on Mondays to Fridays from 9.00 a.m. to 5.00 p.m., during the period from the date the Rights cum Warrants Issue commences up to 5.30 p.m. on 15 July 2024 (or such other time(s) and/or date(s) as may be announced from time to time by or on behalf of the Company).

For practical reasons and in order to avoid any violation of the securities legislation applicable in countries other than Singapore, the Offer Information Statement and its accompanying documents have not been and will not be despatched to Foreign Shareholders or into any jurisdiction outside Singapore. Accordingly, Foreign Shareholders will not be entitled to participate in the Rights cum Warrants Issue. No provisional allotment of the Rights Shares with Warrants has been made or will be made to Foreign Shareholders and no purported acceptance thereof or application therefor by any Foreign Shareholder will be valid.

The Company will make further announcement(s) in relation to the Rights cum Warrants Issue, as and when appropriate.

IX BIOPHARMA LTD.
BY ORDER OF THE BOARD

Eddy Lee Yip Hang
Chairman & CEO
1 July 2024

IMPORTANT NOTICE

This announcement is for information only and does not constitute or form part of any offer or invitation to sell or issue or subscribe for, or any solicitation of any offer to acquire, any Rights Shares with Warrants or to take up any entitlements to Rights Shares with Warrants in any jurisdiction in which such an offer or solicitation is unlawful. No person should acquire any Rights Shares with Warrants except on the basis of the information contained in the offer information statement lodged by the Company with the Singapore Exchange Securities Trading Limited, acting as agent on behalf of the Monetary Authority of Singapore. The information contained in this announcement is not for release, publication or distribution to persons in the United States and should not be distributed, forwarded to or transmitted in or into any jurisdiction where to do so might constitute a violation of applicable securities laws or regulations. The issue, exercise or sale of Rights Shares with Warrants and the acquisition or purchase of the Rights Shares with Warrants are subject to specific legal or regulatory restrictions in certain jurisdictions. The Company assumes no responsibility in the event there is a violation by any person of such restrictions.

The distribution of this announcement into jurisdictions other than Singapore may be restricted by law. Persons into whose possession this announcement and such other documents come should inform themselves about and observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction. Neither the content of the Company's website nor any website accessible by hyperlinks on the Company's website is incorporated in, or forms part of, this announcement.

This announcement has been reviewed by the Company's Sponsor, UOB Kay Hian Private Limited ("**Sponsor**").

This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr. Lance Tan, Senior Vice President, at 8 Anthony Road, #01-01, Singapore 229957, telephone: (65) 6590 6881.